CIPLA - IntraDay Trade Analysis with Live Signals

Last Updated Time : 20 Dec 25, 07:02 am

IntraDay Trade Rating: 3.8

📊 Analysis: CIPLA is trading at 1,517 ₹, right at its 200 DMA (1,517 ₹) and slightly below 50 DMA (1,522 ₹), reflecting short-term caution but medium-term stability. RSI at 43.5 indicates neutral-to-weak momentum, while MACD (-7.85) signals bearish undertone. Volume (11,78,332) is above average (9,68,344), showing strong intraday participation. Fundamentals remain solid with debt-free balance sheet and strong ROCE, but intraday sentiment is cautious.

💡 Optimal Buy Price: 1,510–1,520 ₹ if price stabilizes near support.

🎯 Profit-taking Exit Levels: 1,540 ₹ (first resistance), 1,560 ₹ (next resistance near 50 DMA).

🛡️ Stop-loss / Loss Protection: 1,495 ₹ (below intraday support).

⏱️ If Already Holding: Exit if price fails to hold above 1,510 ₹ or RSI drops below 42 with declining volume. Momentum exit can be triggered near 1,540–1,550 ₹ if upward move lacks strength.

Positive

• ✅ Debt-free balance sheet (Debt-to-equity: 0.00).
• ✅ Strong ROCE at 20.1% and ROE at 16.0%.
• ✅ EPS at 67.3 ₹ supports valuation strength.
• ✅ Volume above average, showing strong intraday participation.
• ✅ 52-week index return at 57.0%, reflecting sector momentum.

Limitation

• ⚠️ Current price below 50 DMA, showing short-term weakness.
• ⚠️ RSI at 43.5 reflects weak momentum.
• ⚠️ MACD (-7.85) indicates bearish undertone.
• ⚠️ Quarterly PAT decline (1,211 Cr. vs 1,303 Cr.).

Company Negative News

• 📉 FII holding reduced (-0.70%).
• 📉 Sequential PAT decline (1,211 Cr. vs 1,303 Cr.).

Company Positive News

• 📈 DII holding increased (+1.00%).
• 📈 Quarterly profit variation positive at 2.75% YoY.

Industry

• 🏭 Industry P/E at 30.6, higher than company’s 23.6, showing undervaluation.
• 🏭 Sector momentum strong with 52w index return at 57.0%.

Conclusion

📌 CIPLA is a moderate intraday candidate with cautious upside. Buy near 1,510–1,520 ₹ with stop-loss at 1,495 ₹. Exit around 1,540–1,560 ₹ if momentum sustains. Strong fundamentals support long-term view, but weak RSI and MACD suggest intraday trades should be closely monitored.

Would you like me to extend this into a peer benchmarking overlay so you can compare CIPLA against other pharma sector stocks for intraday confirmation?